11.01
+7.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Climb Bio
From its filings with the US Securities and Exchange Commission
Climb Bio is based in Wellesley Hills, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CLYM. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $59.9m. At that date it held total assets of $167.7m and shareholders' equity of $160.5m.
We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for patients living with immune-mediated diseases. We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development pathways, and the potential to address multiple indications.
We are developing our product candidates for multiple immune-mediated diseases, as summarized in the pipeline figure below.
Our lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. CD19 plays a mechanistic role across all stages of B-cell development, and emerging clinical evidence continues to support the importance of CD19 in immune-mediated diseases. By targeting CD19, budoprutug has the potential to provide rapid, profound, and durable reductions in B cells and pathogenic autoantibodies, which may allow for a disease-modifying therapeutic approach. We have focused our initial development strategy for budoprutug on primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE), which we believe each offer a strong mechanistic rationale for CD19-directed therapy.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Aug 2021
- Employees
- 30
- Website
- eliemtx.com ↗
- Head office
- 20 WILLIAM STREET, WELLESLEY HILLS, MA
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Douglas WilliamsIndependent Chairman of the Board$98,389
- Dr. Aoife BrennanPresident, Chief Executive Officer, Director, since 2024$6.0m
- Dr. Susan AltschullerChief Financial Officer, Treasurer
- Ms. Cindy DriscollSenior Vice President - Finance
- Dr. Andrew LevinDirector, since 2018$248,410
- Dr. Stephen ThomasDirector$1.7m
- Mr. Alexander CumboIndependent Director
- Ms. Kimberlee DrapkinIndependent Director
- Dr. Judith DunnIndependent Director$111,122
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 42
- Social
- 66
- Governance
- 17
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Climb Bio Inc focuses on Kv7.2/3 potassium channel openers for epilepsy and pain treatments.
- ETX-123 is a lead candidate with clinical data in depression and pain management.
- The company has 30 employees and operates in the biotechnology sector.
Weaknesses
- Climb Bio Inc has only 30 employees, which may limit research capacity.
- The company is a clinical-stage biotechnology firm with no approved products yet.
- ETX-123 is still in development without regulatory approval.
Opportunities
- The biotechnology sector in the US offers growth potential for new therapies.
- Unmet needs in psychiatry and epilepsy present market opportunities.
- Kv7.2/3 channel mechanism has clinical validation for multiple disorders.
Threats
- Biotechnology companies face high R&D costs and regulatory hurdles.
- Competition in the nervous system disorder treatment market is intense.
- Clinical trial failures could delay product development timelines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.